Clinical Characteristics and Outcome of Patients With COPD With Pneumonia

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Study on the Clinical Characteristics and Outcome of Patients With COPD Combined With Pneumonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04966026
• Other study ID #: M2017017
• Status: Completed
• Start date: March 1, 2017
• Est. completion date: May 30, 2018

Study information

• Verified date: May 2018
• Source: Peking University Third Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To identify the clinical characteristics of patients with chronic obstructive pulmonary disease (COPD) combined with community-acquired pneumonia (CAP) and the factors influencing clinical transition.

Description:

To identify the clinical characteristics of patients with chronic obstructive pulmonary disease (COPD) combined with community-acquired pneumonia (CAP) and the factors influencing clinical transition.Compared to other chronic airway diseases, COPD patients can often have CAP in combination, but there is a lack of comparative studies between COPD patients with CAP and non-COPD patients with CAP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 143
• Est. completion date: May 30, 2018
• Est. primary completion date: February 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. CAP meets the diagnostic criteria published in 2016 Chinese CAP diagnosis and treatment guidelines; CPOPD and AECOPD meet the diagnostic criteria published in Chinese 2013 COPD diagnosis and treatment guidelines;

2. Age ? 40years.

Exclusion Criteria:

1. age <40years;

2. pregnancy;

3. positive for human immunodeficiency virus (HIV) antibodies;

4. suspected or confirmed tuberculosis or fungal infection of the lung.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases, Obstructive
• Pneumonia
• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• No inervention
No inervention

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mortality rate	mortality rate	Day 28 from hospitalization
Secondary	Number of days in hospital	Number of days in hospital	through study completion, an average of 1 year
Secondary	number of days in ICU	number of days in ICU	through study completion, an average of 1 year
Secondary	number of days on mechanical ventilation	number of days on mechanical ventilation	through study completion, an average of 1 year
Secondary	cause of using antimicrobial drugs	Days of using antimicrobial drugs during hospitalization	through study completion, an average of 1 year
Secondary	hospital fees	hospital fees.	through study completion, an average of 1 year